Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,604 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of a novel CDK7 inhibitor YPN-005 in small cell lung cancer.
Choi YJ, Lee H, Kim DS, Kim DH, Kang MH, Cho YH, Choi CM, Yoo J, Lee KO, Choi EK, Lee JC, Rho JK. Choi YJ, et al. Among authors: kim ds, kim dh. Eur J Pharmacol. 2021 Sep 15;907:174298. doi: 10.1016/j.ejphar.2021.174298. Epub 2021 Jul 3. Eur J Pharmacol. 2021. PMID: 34224696
The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancer.
Choi YJ, Kim DS, Hoon Sung Y, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Choi YJ, et al. Among authors: kim ds, kim se, kim dh, kim js. Cancer Res. 2022 Jun 14:canres.0394.2022-2-3 21:03:12.200. doi: 10.1158/0008-5472.CAN-22-0394. Online ahead of print. Cancer Res. 2022. PMID: 35700239 Retracted.
Generation of genetically engineered mice for lung cancer with mutant EGFR.
Kim DS, Ji W, Kim DH, Choi YJ, Im K, Lee CW, Cho J, Min J, Woo DC, Choi CM, Lee JC, Sung YH, Rho JK. Kim DS, et al. Among authors: kim dh. Biochem Biophys Res Commun. 2022 Dec 3;632:85-91. doi: 10.1016/j.bbrc.2022.09.104. Epub 2022 Sep 30. Biochem Biophys Res Commun. 2022. PMID: 36206598
Correction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer.
Choi YJ, Kim DS, Sung YH, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Choi YJ, et al. Among authors: kim ds, kim se, kim dh, kim js. Cancer Res. 2022 Aug 25:OF1. doi: 10.1158/0008-5472.CAN-22-2377. Online ahead of print. Cancer Res. 2022. PMID: 36006687 No abstract available.
Retraction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer.
Choi YJ, Kim DS, Sung YH, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Choi YJ, et al. Among authors: kim ds, kim se, kim dh, kim js. Cancer Res. 2022 Aug 26:OF1. doi: 10.1158/0008-5472.CAN-22-2507. Online ahead of print. Cancer Res. 2022. PMID: 36018295 No abstract available.
Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA.
Bae M, Kim G, Lee TR, Ahn JM, Park H, Park SR, Song KB, Jun E, Oh D, Lee JW, Park YS, Song KW, Byeon JS, Kim BH, Sohn JH, Kim MH, Kim GM, Chie EK, Kang HC, Kong SY, Woo SM, Lee JE, Ryu JM, Lee J, Kim D, Ki CS, Cho EH, Choi JK. Bae M, et al. Nat Commun. 2023 Apr 10;14(1):2017. doi: 10.1038/s41467-023-37768-3. Nat Commun. 2023. PMID: 37037826 Free PMC article.
4,604 results